In the interview, Yu Weishi mentioned his values ​​and employment concept - honesty and diligence. The two seemingly ordinary ideas gave Yuekang a business-industry, domestic-international, and Imitation of the entire industrial chain to the original research way out -
From the congested downtown area of ​​Beijing, it took a car and headed south. After about half an hour's drive, there was an industrial zone in Beijing, including the economic and technological development zone, with neat planning and Europe and the United States. Yuekang Pharmaceutical Group was located here. Entering the hall of Yuekang Group office building, a statue of Deng Xiaoping standing more than 2 meters high stands in the center of the hall. There is a line of Deng Xiaoping's handwritten version of the golden copper word “Development is the absolute principleâ€. Behind the front desk of the company, the "honesty and diligence" plaque signed by Yu Weishi is very eye-catching. The whole hall looks simple, dignified and elegant. The reporter visited many companies, but this feeling of Yue Kang is the first time. With the various outlines of Wei Shi’s own image, the reporter went to the office of the Chairman of the sixth floor. The lift opened and Yu Weishi, the founder of Yuekang Pharmaceutical Group, had already waited at the entrance of the elevator. This is a smiling, honest and tough elderly person.
When asked why the company erected a statue of Deng Xiaoping, Yu Weishi opened his voice: "Looking back at the past, we experienced a lot of hardship. It was Deng Xiaoping's policy of reform and opening up, which made the country prosperous and strong, and people's lives are happy. I think every one The Chinese, and even the global Chinese, should thank Deng Xiaoping."
In 1988, Yu Weishi gave up the work of Anhui Taihe State-owned Pharmaceutical Co., Ltd. and went alone to the forefront of reform and opening up - Guangdong engaged in the pharmaceutical trade business, and represented the nationwide distribution right of imported cephalosporin products from Italy. The imported cephalosporin drugs of the year were considered to be sky-high drugs. In order to reduce drug prices, Yu Weishi repeatedly negotiated with foreign companies to import cephalosporin raw materials from abroad and processed it in China, greatly reducing the price and meeting the health needs of more patients. . With the expansion of business, he was given a cephalic name of “Cephamonium†in the industry.
Entrepreneurship is hard. Many people today are always complaining that they are not in a good time when they look at the “goers†of the year and think that it is an opportunity all year round. When talking about Yue Kang's entrepreneurial journey, Yu Weishi humbly laughed and called himself a lucky one. But from his description, we can feel that Yue Kang's success is not fortunate and simple, including Wei Shi’s career. Perseverance, integrity and responsibility. Today, these concepts are passed down from generation to generation as Yuekang’s corporate culture and spirit.
Feng Lun, chairman of Vantone Investment Holding Co., Ltd., has “define†the correct values: “The right values ​​allow us to do the right thing, do expensive things, and do long-term and meaningful things. The wrong values ​​lead us. What the company does wrong may save some money now, but in the future it will pay a greater price and even be eliminated.†This sentence applies to the current pharmaceutical industry, and Yu Wei Shi’s following three issues Answering or can give him and his values ​​a perfect comment -
How to stabilize market confidence after the "question capsule" incident?
"The quality of medicines is only one hundredth and ninety-nine is equal to zero."
At present, the Chinese pharmaceutical industry is undergoing a major transformation. The recent "problem capsule" incident has pushed the pharmaceutical industry to the cusp of public opinion. A series of food safety and drug quality incidents have caused the public to seriously question the lack of corporate responsibility.
“I think that doing business is to be responsible. Pharmaceutical companies should do a better job of quality and shoulder greater social responsibility.†The quality principle established by Yu Weishi for Yuekang is that “the quality of medicines is only one hundred percent, and ninety-nine equals zero. "The attitude taken by the team he leads is zero tolerance for quality defects." Since Yuekang tablets and capsules production lines have passed the EU certification, the EU GMP standard requires that the raw and auxiliary materials for drugs must be inspected for the factory. To this end, Yuekang purchased a set of quality testing equipment and strictly screened the upstream suppliers to ensure that Drug quality.
Therefore, after the media exposed some capsules with excessive chromium, causing panic among the people and distrust of the capsules, Yuekang publicly issued a capsule quality commitment letter to all distributors and the society, indicating the company’s product production and quality inspection control. The process, solemnly promised to bear all the consequences of product quality. The issuance of the letter of commitment gave the distributors a “centering pill†and stabilized market confidence.
"If you are in the pharmaceutical industry, you can't evade the responsibility." Yu Wei Shi said: "Even if it is a qualified drug, the manufacturer must bear the corresponding responsibility after the factory." In order to ensure the safety of the drug as much as possible, Yue Kang in addition to strengthening In addition to the internal production quality control, a great deal of work has been done on the transportation and clinical use safety of medicines: specialized drug container trucks have been set up, drug transportation teams have been established, and pharmaceutical experts have been entrusted with the preparation of the “Handbook of Safe Use of Cephalosporins Antibiotic Injections†to guide them. The rational use of drugs at the grass-roots level ensures the safety of the lives of patients and truly establishes a full-scale quality control system for the use of drugs from production to clinical use.
It is precisely because of the demand for the quality of medicines and the steadfastness of corporate responsibilities that Yuekang continues to win the trust of customers and the market.
How to first seize the international market in the first 10 years of its establishment?
"Thinking is the way to go and it's better to be late to do it."
During the 67th National Pharmaceutical Fair held in Hefei, the “China Formulation Internationalization Strategy High-end Forum†co-sponsored by China Pharmaceutical Enterprise Management Association and the China Chamber of Commerce for the Import and Export of Medicines and Health Products, for the first time announced the internationalization of preparations through developed countries in Europe and America. For the list of 15 companies that have been certified, Yuekang Pharmaceutical Group has been awarded the “China Pharmaceutical Enterprise Internationalization Leading Enterprise Certification†certificate as it has passed the EU cGMP certification list. A company that has built a plant for only 10 years has seized the international market gimmick in just a few years. What is the secret behind this? The Yuekang Exhibition Hall neatly displays a row of medicine boxes that are printed in English, Russian, Arabic and other languages. It is understood that Yuekang already has 70 items of pharmaceutical products in Russia, Pakistan and Southeast Asia, Central Asia. More than 30 countries and regions such as Latin America and Africa have completed their export registrations. The export products are mainly injections, and the export value has doubled year by year. In 2011, after the EU cGMP certification, the European export business has now started.
Why can a young company go so far in the international market? "The idea determines the way out!" explains Yu Weishi. It should be said that engaging in the international trade of pharmaceutical imports in the past allowed Yu Weishi to draw on many international elements and opened up his international perspective. In 2001, Yuekang laid the foundation and built a factory in Beijing. Yu Weisi placed the domestic and international markets on the same starting line at the same time. Yuekang began to apply for foreign export registration at the same time as it obtained domestic drug approvals. Due to the cooperation with OEM companies in Germany, Australia, and other developed countries, Yuekang has learned a lot of advanced pharmaceutical management experience and models, laying a solid foundation for further international certification.
At present, Yue Kang's International Division has expanded to a team of 100 people. The company regards internationalization as a strategic goal of the company. After passing the EU GMP certification, the company has set up a special team to start applying for US FDA certification. At the same time, Yuekang’s four-phase project under construction in Beijing and Yuekang Innovative Pharmaceuticals International Industrial Park are designed and built according to the US FDA standard.
Why do you attach importance to internationalization? Yu Weishi said: "Internationalization is a standard, and it is the direction of the future. It is better to do it later. My wish is to allow our Chinese people to spend less on imported quality medicine."
How to break through the homogenous competition predicament?
"Innovation, constantly improving its own pharmaceutical industry chain"
The current difficulties faced by the Chinese pharmaceutical industry are rooted in too many homogenous competitions. As a national strategic emerging industry, the biopharmaceutical industry only depends on innovation in the future.
"Yuekang started with imitation products. After several years of development and accumulation, we have continuously increased investment in R&D. Now we have shifted from cephalosporins to digestive, cardio-cerebral vascular, anti-tumor and biological polypeptide products." In the future of Yuekang, Yu Wei Shi first mentions innovation. Currently, Yuekang has not only established a new drug R&D team of 100 people, but also cooperated with Beijing and foreign scientific research institutes and institutions to establish a new drug development cooperation system for the purpose of enterprise demand and service industry, and established Yuekang Enterprise Technology. Center and Engineering Technology Center.
"Future Yuekang will continue to improve its own pharmaceutical industry chain." Yu Wei Shi said. At the end of the interview, the reporter was walking out of Yuekang's gate and inadvertently looked back and saw the line of red characters on the wall facing the front: “Technical innovation, management innovation, and institutional innovation.†We believe that the Yue Kang of innovation will be better tomorrow!
From the congested downtown area of ​​Beijing, it took a car and headed south. After about half an hour's drive, there was an industrial zone in Beijing, including the economic and technological development zone, with neat planning and Europe and the United States. Yuekang Pharmaceutical Group was located here. Entering the hall of Yuekang Group office building, a statue of Deng Xiaoping standing more than 2 meters high stands in the center of the hall. There is a line of Deng Xiaoping's handwritten version of the golden copper word “Development is the absolute principleâ€. Behind the front desk of the company, the "honesty and diligence" plaque signed by Yu Weishi is very eye-catching. The whole hall looks simple, dignified and elegant. The reporter visited many companies, but this feeling of Yue Kang is the first time. With the various outlines of Wei Shi’s own image, the reporter went to the office of the Chairman of the sixth floor. The lift opened and Yu Weishi, the founder of Yuekang Pharmaceutical Group, had already waited at the entrance of the elevator. This is a smiling, honest and tough elderly person.
When asked why the company erected a statue of Deng Xiaoping, Yu Weishi opened his voice: "Looking back at the past, we experienced a lot of hardship. It was Deng Xiaoping's policy of reform and opening up, which made the country prosperous and strong, and people's lives are happy. I think every one The Chinese, and even the global Chinese, should thank Deng Xiaoping."
In 1988, Yu Weishi gave up the work of Anhui Taihe State-owned Pharmaceutical Co., Ltd. and went alone to the forefront of reform and opening up - Guangdong engaged in the pharmaceutical trade business, and represented the nationwide distribution right of imported cephalosporin products from Italy. The imported cephalosporin drugs of the year were considered to be sky-high drugs. In order to reduce drug prices, Yu Weishi repeatedly negotiated with foreign companies to import cephalosporin raw materials from abroad and processed it in China, greatly reducing the price and meeting the health needs of more patients. . With the expansion of business, he was given a cephalic name of “Cephamonium†in the industry.
Entrepreneurship is hard. Many people today are always complaining that they are not in a good time when they look at the “goers†of the year and think that it is an opportunity all year round. When talking about Yue Kang's entrepreneurial journey, Yu Weishi humbly laughed and called himself a lucky one. But from his description, we can feel that Yue Kang's success is not fortunate and simple, including Wei Shi’s career. Perseverance, integrity and responsibility. Today, these concepts are passed down from generation to generation as Yuekang’s corporate culture and spirit.
Feng Lun, chairman of Vantone Investment Holding Co., Ltd., has “define†the correct values: “The right values ​​allow us to do the right thing, do expensive things, and do long-term and meaningful things. The wrong values ​​lead us. What the company does wrong may save some money now, but in the future it will pay a greater price and even be eliminated.†This sentence applies to the current pharmaceutical industry, and Yu Wei Shi’s following three issues Answering or can give him and his values ​​a perfect comment -
How to stabilize market confidence after the "question capsule" incident?
"The quality of medicines is only one hundredth and ninety-nine is equal to zero."
At present, the Chinese pharmaceutical industry is undergoing a major transformation. The recent "problem capsule" incident has pushed the pharmaceutical industry to the cusp of public opinion. A series of food safety and drug quality incidents have caused the public to seriously question the lack of corporate responsibility.
“I think that doing business is to be responsible. Pharmaceutical companies should do a better job of quality and shoulder greater social responsibility.†The quality principle established by Yu Weishi for Yuekang is that “the quality of medicines is only one hundred percent, and ninety-nine equals zero. "The attitude taken by the team he leads is zero tolerance for quality defects." Since Yuekang tablets and capsules production lines have passed the EU certification, the EU GMP standard requires that the raw and auxiliary materials for drugs must be inspected for the factory. To this end, Yuekang purchased a set of quality testing equipment and strictly screened the upstream suppliers to ensure that Drug quality.
Therefore, after the media exposed some capsules with excessive chromium, causing panic among the people and distrust of the capsules, Yuekang publicly issued a capsule quality commitment letter to all distributors and the society, indicating the company’s product production and quality inspection control. The process, solemnly promised to bear all the consequences of product quality. The issuance of the letter of commitment gave the distributors a “centering pill†and stabilized market confidence.
"If you are in the pharmaceutical industry, you can't evade the responsibility." Yu Wei Shi said: "Even if it is a qualified drug, the manufacturer must bear the corresponding responsibility after the factory." In order to ensure the safety of the drug as much as possible, Yue Kang in addition to strengthening In addition to the internal production quality control, a great deal of work has been done on the transportation and clinical use safety of medicines: specialized drug container trucks have been set up, drug transportation teams have been established, and pharmaceutical experts have been entrusted with the preparation of the “Handbook of Safe Use of Cephalosporins Antibiotic Injections†to guide them. The rational use of drugs at the grass-roots level ensures the safety of the lives of patients and truly establishes a full-scale quality control system for the use of drugs from production to clinical use.
It is precisely because of the demand for the quality of medicines and the steadfastness of corporate responsibilities that Yuekang continues to win the trust of customers and the market.
How to first seize the international market in the first 10 years of its establishment?
"Thinking is the way to go and it's better to be late to do it."
During the 67th National Pharmaceutical Fair held in Hefei, the “China Formulation Internationalization Strategy High-end Forum†co-sponsored by China Pharmaceutical Enterprise Management Association and the China Chamber of Commerce for the Import and Export of Medicines and Health Products, for the first time announced the internationalization of preparations through developed countries in Europe and America. For the list of 15 companies that have been certified, Yuekang Pharmaceutical Group has been awarded the “China Pharmaceutical Enterprise Internationalization Leading Enterprise Certification†certificate as it has passed the EU cGMP certification list. A company that has built a plant for only 10 years has seized the international market gimmick in just a few years. What is the secret behind this? The Yuekang Exhibition Hall neatly displays a row of medicine boxes that are printed in English, Russian, Arabic and other languages. It is understood that Yuekang already has 70 items of pharmaceutical products in Russia, Pakistan and Southeast Asia, Central Asia. More than 30 countries and regions such as Latin America and Africa have completed their export registrations. The export products are mainly injections, and the export value has doubled year by year. In 2011, after the EU cGMP certification, the European export business has now started.
Why can a young company go so far in the international market? "The idea determines the way out!" explains Yu Weishi. It should be said that engaging in the international trade of pharmaceutical imports in the past allowed Yu Weishi to draw on many international elements and opened up his international perspective. In 2001, Yuekang laid the foundation and built a factory in Beijing. Yu Weisi placed the domestic and international markets on the same starting line at the same time. Yuekang began to apply for foreign export registration at the same time as it obtained domestic drug approvals. Due to the cooperation with OEM companies in Germany, Australia, and other developed countries, Yuekang has learned a lot of advanced pharmaceutical management experience and models, laying a solid foundation for further international certification.
At present, Yue Kang's International Division has expanded to a team of 100 people. The company regards internationalization as a strategic goal of the company. After passing the EU GMP certification, the company has set up a special team to start applying for US FDA certification. At the same time, Yuekang’s four-phase project under construction in Beijing and Yuekang Innovative Pharmaceuticals International Industrial Park are designed and built according to the US FDA standard.
Why do you attach importance to internationalization? Yu Weishi said: "Internationalization is a standard, and it is the direction of the future. It is better to do it later. My wish is to allow our Chinese people to spend less on imported quality medicine."
How to break through the homogenous competition predicament?
"Innovation, constantly improving its own pharmaceutical industry chain"
The current difficulties faced by the Chinese pharmaceutical industry are rooted in too many homogenous competitions. As a national strategic emerging industry, the biopharmaceutical industry only depends on innovation in the future.
"Yuekang started with imitation products. After several years of development and accumulation, we have continuously increased investment in R&D. Now we have shifted from cephalosporins to digestive, cardio-cerebral vascular, anti-tumor and biological polypeptide products." In the future of Yuekang, Yu Wei Shi first mentions innovation. Currently, Yuekang has not only established a new drug R&D team of 100 people, but also cooperated with Beijing and foreign scientific research institutes and institutions to establish a new drug development cooperation system for the purpose of enterprise demand and service industry, and established Yuekang Enterprise Technology. Center and Engineering Technology Center.
"Future Yuekang will continue to improve its own pharmaceutical industry chain." Yu Wei Shi said. At the end of the interview, the reporter was walking out of Yuekang's gate and inadvertently looked back and saw the line of red characters on the wall facing the front: “Technical innovation, management innovation, and institutional innovation.†We believe that the Yue Kang of innovation will be better tomorrow!
Recessed LED Panel With Back Light
Ningbo Wellway Optoelectronic Technology Co.,Ltd , https://www.wellwayopto.com